In a pivotal step toward enhancing cancer treatment, Oregon Therapeutics has joined forces with Lantern Pharma to escalate the development of a pivotal cancer drug, XCE853. This collaborative venture showcases AI's potential to transform medical innovations and potentially bring groundbreaking
The Summit on Men's Health: A Focus on Overactive Bladder and BPH Vibegron's emergence as a potential treatment for overactive bladder (OAB) offers new hope to men concurrently managing benign prostatic hyperplasia (BPH). Recent data from Sumitomo Pharma America, Inc. (SMPA) presented
In the evolving landscape of pharmaceuticals, the strategic partnership between Lantern Pharma and Oregon Therapeutics marks a significant milestone in the use of artificial intelligence (AI) for drug development. This collaboration centers on the advanced cancer drug candidate XCE853, an inhibitor
Lantern Pharma's LP-300 signals a significant advancement in the fight against non-small cell lung cancer (NSCLC), particularly in never-smokers—a group seeing elevated incidence rates, notably in East Asia. This promising therapeutic option stands out as NSCLC treatments often overlook the u
In a landmark multi-ancestry study by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), researchers have discovered 50 new genetic regions tied to the risk of kidney cancer. This extensive investigation involved a massive cohort comprising 29,020 kidney cancer
In the fight against kidney cancer, ALLO-316, created by Allogene Therapeutics, stands out in the vanguard with its CAR T-cell therapy. This breakthrough offers new hope against renal cell carcinoma (RCC), a type notorious for its defiance against traditional treatments. As ALLO-316 progresses
